Breaking News
9 hours ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Sun Pharma's Rs. 33,500 crore cumulative R&D spend raises near-term demands on process validation, tech transfer, and global regulatory submissions.
Pharma Now Editorial Team

NATCO Pharma raises its Adcock Ingram stake to 49% in a Rs. 1,069 crore deal, triggering dual SAHPRA-CDSCO compliance requirements.
Pharma Now Editorial Team

Gennova Biopharma divests its mRNA platform to Immunoscript for Rs. 139.5 crore, reflecting post-COVID commercial pressures on mRNA manufacturing.
Pharma Now Editorial Team

FDA finalizes PFC guidance for priority ANDAs under GDUFA III, giving regulatory teams a concrete framework for optimizing review timelines.
Pharma Now Editorial Team
